Boothbay Fund Management’s VistaGen Therapeutics VTGN Stock Holding History

Boothbay Fund Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76.9K	Hold	134,571	–	–	﹤0.01%	1893
2025 Q4	$89.1K	Sell	134,571 -62,453	-32%	-$226K	﹤0.01%	1751
2025 Q3	$699K	Buy	197,024 +19,166	+11%	+$57.3K	0.01%	997
2025 Q2	$356K	Hold	177,858	–	–	0.01%	1034
2025 Q1	$445K	Buy	177,858 +155,443	+693%	+$440K	0.01%	903
2024 Q4	$66.1K	Buy	+22,415	New	+$63.1K	﹤0.01%	1328
2023 Q4	–	Sell	-46,895	Closed	-$246K	–	2023
2023 Q3	$246K	Buy	+46,895	New	+$208K	0.01%	1342
2022 Q2	–	Sell	-2,545	Closed	-$95K	–	2702
2022 Q1	$95K	Buy	2,545 +1,016	+66%	+$44.3K	﹤0.01%	2111
2021 Q4	$89K	Sell	1,529 -402	-21%	-$26.2K	﹤0.01%	1728
2021 Q3	$159K	Sell	1,931 -2,316	-55%	-$201K	﹤0.01%	1651
2021 Q2	$401K	Sell	4,247 -5,777	-58%	-$428K	0.01%	1118
2021 Q1	$641K	Sell	10,024 -5,557	-36%	-$371K	0.02%	810
2020 Q4	$907K	Buy	+15,581	New	+$398K	0.03%	530

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's VTGN Position: Q1 2026 in Review

Boothbay Fund Management held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 134,571 shares worth $76.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

Boothbay Fund Management first reported a position in VTGN in Q4 2020 and has held it in 13 quarters since. The position peaked at $907K in Q4 2020. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Boothbay Fund Management held 134,571 shares of VistaGen Therapeutics worth $76.9K as of Q1 2026.
Boothbay Fund Management left its VistaGen Therapeutics share count unchanged in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1893 holding.
Boothbay Fund Management first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 13 quarters since.
Boothbay Fund Management's VistaGen Therapeutics position peaked at $907K in Q4 2020.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.